NEW YORK (GenomeWeb News) – Quidel said after the close of the market Tuesday that revenues in the third quarter narrowed by a fraction of 1 percent year over year, missing the consensus Wall Street estimate.

Company officials also said that the firm's plans for its molecular diagnostic products remain on schedule.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.